Merck, 5005540001, mTOR Activator, MHY1485

General description
MHY1485, a small-molecule activator of the mammalian target of rapamycin (mTOR), exerts an inhibitory effect on the autophagic process by preventing the fusion between autophagosomes and lysosomes, resulting in the accumulation of LC3II protein and the enlargement of autophagosomes. It can also protect osteoblasts from dexamethasone-induced damage by inhibiting the mitochondrial death pathway provoked by dexamethasone.
Application
mTOR Activator, MHY1485 has been used to activate the mammalian target of rapamycin (mTOR) pathway in mice with Parkinson disease (PD) to reverse the effects of tumor necrosis factor α–induced protein 3 (TNFAIP3) on the mitigation of injury in mice and in SK-N-SH cells induced with 1-Methyl-4-phenylpyridinium (MPP+).
Biochem/physiol Actions
Cell permeable: yes
Reversible: yes
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Choi, Y. J., et al. 2012. PLoS. One.7, e43418.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)